Viking’s VK2735 looks like ‘heavyweight contender,’ says H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating and $21 price target on Viking Therapeutics shares after the company announced results from its Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735. The firm says the data provide "a very promising initial look" at VK2735’s potential in obesity and given the recent surge in popularity of prescribing GLP-1/GIP modulators like liraglutide and semaglutide for weight loss its believes VK2735 is "becoming increasingly well-positioned in the space" and emerging as "a heavyweight contender."